Literature DB >> 11754400

Successful treatment of high titer inhibitors in mild hemophilia A with avoidance of factor VIII and immunosuppressive therapy.

D Robbins1, R Kulkarni, R Gera, A B Scott-Emuakpor, K Bosma, J A Penner.   

Abstract

We describe two patients with mild hemophilia A (MHA) who developed high titer inhibitor (HTI) following intensive recombinant factor VIII (rFVIII) concentrate replacement for surgery and trauma. Intranasal desmopressin was instituted shortly following immunosuppressive therapy (IST) and activated prothrombin complex concentrate (APCC) in one case, and following APCC alone in the second case. Avoidance of factor VIII (FVIII) coupled with intranasal desmopressin prophylaxis three times a week resulted in undetectable inhibitor levels. Both patients have had no further bleeding episodes and have been maintained on desmopressin prophylaxis prior to activity for the past 2 to 3 years. Recombinant factor VIIa (rFVIIa) was used successfully prior to a second surgery in one patient without complication. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11754400     DOI: 10.1002/ajh.1176

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  3 in total

1.  Eradication of factor VIII inhibitors in patients with mild and moderate hemophilia A.

Authors:  Christine L Kempton; Geoff Allen; Jeffrey Hord; Rebecca Kruse-Jarres; Rajiv K Pruthi; Christopher Walsh; Guy Young; J Michael Soucie
Journal:  Am J Hematol       Date:  2012-06-26       Impact factor: 10.047

2.  Factor VIII inhibitors in hemophilia A: rationale and latest evidence.

Authors:  Char Witmer; Guy Young
Journal:  Ther Adv Hematol       Date:  2013-02

3.  Clinical Care of Bone Health in Patients on the Immune Tolerance Induction's Protocols With an Immunosuppressive Agent for Inhibitor Eradication in Hemophilia.

Authors:  Zahra Rezaieyazdi; Hassan Mansouritorghabeh
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.